Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
SLXN Stock Chart & Stats
$3.44
-$0.10(-4.76%)
At close: 4:00 PM EST
$3.44
-$0.10(-4.76%)
Day’s Range― - ―
52-Week Range$3.25 - $63.45
Previous CloseN/A
Volume52.80K
Average Volume (3M)964.79K
Market Cap
$7.48M
Enterprise Value$7.25M
Total Cash (Recent Filing)$3.47M
Total Debt (Recent Filing)$3.70M
Price to Earnings (P/E)―
Beta-0.10
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.98
Shares Outstanding2,123,892
10 Day Avg. Volume77,448
30 Day Avg. Volume964,790
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-249.94
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$24.00Price Target Upside597.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical PotentialSIL-204 has demonstrated anti-tumor activity in five different KRAS mutated cancer types and inhibition across eight different KRAS mutations, supporting its clinical potential and expanding its market opportunity.
Preclinical SuccessSilexion recently announced additional highly positive preclinical data finding SIL-204 demonstrated 97% tumor growth inhibition in a previously untested KRAS mutated line and successfully showed inhibition in both pancreatic and colorectal cancers.
Regulatory SupportThe FDA awarding daraxonrasib a CNPV suggests the FDA is highly supportive of the KRAS targeting approach, indicating potential support for Silexion's IND filing in the U.S.
Bears Say
Price Target ReductionThe 12-month price target was reduced to $24.00 due to dilution from the recent capital raise and potential additional dilution for future raises to fund the clinical study.
Stock PerformanceShares are trading down ~35% following the warrant exercises.
Silexion Therapeutics News
SLXN FAQ
What was Silexion Therapeutics’s price range in the past 12 months?
Silexion Therapeutics lowest stock price was $3.25 and its highest was $63.45 in the past 12 months.
What is Silexion Therapeutics’s market cap?
Silexion Therapeutics’s market cap is $7.48M.
When is Silexion Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Silexion Therapeutics’s earnings last quarter?
Silexion Therapeutics released its earnings results on May 13, 2025. The company reported -$3.9 earnings per share for the quarter, missing the consensus estimate of -$3.3 by -$0.6.
Is Silexion Therapeutics overvalued?
According to Wall Street analysts Silexion Therapeutics’s price is currently Undervalued.
Does Silexion Therapeutics pay dividends?
Silexion Therapeutics does not currently pay dividends.
What is Silexion Therapeutics’s EPS estimate?
Silexion Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Silexion Therapeutics have?
Silexion Therapeutics has 2,123,892 shares outstanding.
What happened to Silexion Therapeutics’s price movement after its last earnings report?
Silexion Therapeutics reported an EPS of -$3.9 in its last earnings report, missing expectations of -$3.3. Following the earnings report the stock price went down -4.605%.
Which hedge fund is a major shareholder of Silexion Therapeutics?
Currently, no hedge funds are holding shares in SLXN
Company Description
Silexion Therapeutics
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
SLXN Stock 12 Month Forecast
Average Price Target
$24.00
▲(597.67% Upside)